Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and spinal fusion stimulators. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:ZBH
Previous SymbolNYSE:ZMH
CUSIPN/A
Phone574-267-6131
Debt
Debt-to-Equity Ratio0.70
Current Ratio1.89
Quick Ratio0.96
Price-To-Earnings
Trailing P/E Ratio14.58
Forward P/E Ratio15.30
P/E Growth2.29
Sales & Book Value
Annual Sales$7.82 billion
Price / Sales3.05
Cash Flow$15.5239 per share
Price / Cash7.54
Book Value$59.92 per share
Price / Book1.95
Profitability
EPS (Most Recent Fiscal Year)$8.03
Net Income$1.81 billion
Net Margins22.42%
Return on Equity12.88%
Return on Assets5.95%
Miscellaneous
Employees18,200
Outstanding Shares203,980,000
Market Cap$23.03 billion
OptionableOptionable
Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions
What is Zimmer Biomet's stock symbol?
Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."
How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?
Zimmer Biomet declared a quarterly dividend on Thursday, September 13th. Stockholders of record on Friday, September 28th will be paid a dividend of $0.24 per share on Wednesday, October 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Thursday, September 27th. View Zimmer Biomet's Dividend History.
How were Zimmer Biomet's earnings last quarter?
Zimmer Biomet Holdings Inc (NYSE:ZBH) announced its quarterly earnings results on Friday, October, 26th. The medical equipment provider reported $1.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.03. The medical equipment provider earned $1.84 billion during the quarter, compared to analyst estimates of $1.84 billion. Zimmer Biomet had a return on equity of 12.88% and a net margin of 22.42%. The firm's quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.72 EPS. View Zimmer Biomet's Earnings History.
When is Zimmer Biomet's next earnings date?
What price target have analysts set for ZBH?
22 brokers have issued 12 month target prices for Zimmer Biomet's shares. Their predictions range from $96.00 to $168.00. On average, they expect Zimmer Biomet's stock price to reach $134.6316 in the next year. This suggests a possible upside of 15.0% from the stock's current price. View Analyst Price Targets for Zimmer Biomet.
What is the consensus analysts' recommendation for Zimmer Biomet?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 2 sell ratings, 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Zimmer Biomet.
What are Wall Street analysts saying about Zimmer Biomet stock?
Here are some recent quotes from research analysts about Zimmer Biomet stock:
- 1. BTIG Research analysts commented, "an easy comp led us to believe that 3Q results were beatable. While top-line fell in-line with the Street and EPS was 3 cents higher (which would have satisfied investors in our view), sentiment was hampered by commentary related to FY19 (specifically ongoing margin pressures and lost sales from ZBH’s distribution agreement with BONESUPPORT (BONEX-OM, Not Rated)). Underlying rev. growth of 2.0% Y/Y improved Y/Y (helped by 3Q tenders, ~40bps by our est.) and while GMs were soft (as expected in 3Q), mgmt. commentary indicates ongoing margin pressure into FY19 along with increasing Fx headwinds. Collectively headwinds will lower EPS by $0.15 in FY19, offset by a lower interest expense and tax rate." (10/28/2018)
- 2. According to Zacks Investment Research, "In the past three months, Zimmer Biomet has been observed to outperform its industry. The company’s consistent efforts in product and renovation through research and development raise hopes. The improvement within the company’s global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging. Banking on its firm focus on priority areas like quality remediation, supply recovery efforts and product launches, Zimmer Biomet once again reported strong topline numbers within its S.E.T. On the flip side, the year-over-year decline in earnings made investors jittery. Also, declining sales at Dental affected by price completion was a major disappointment. Further, escalating costs and expenses impacted margins." (10/17/2018)
- 3. Needham & Company LLC analysts commented, "In an 8-K filed this morning, ZBH disclosed that it received a FDA warning letter late Friday, 8/24.The warning letter isn’t a surprise in our view given ZBH’s previous two Form 483s. While we think that the risk of a consent decree has probably increased, we still think it is very unlikely given ZBH’s significant efforts and investments in addressing the Biomet plant issues. We don’t expect any impact to ZBH’s financial results from the warning letter and maintain our Buy rating." (8/27/2018)
- 4. Cantor Fitzgerald analysts commented, "We rate ZBH shares Overweight and have a 12-month price target of $150. ZBH has started a new era with recently hired the CEO of 10 years resigned in July. Under the new CEO near-term challenges persist, but we would expect the company to benefit from Hanson’s broader medtech background. ZBH is the least expensive large-cap medtech stock on a P/E basis, currently trading at a discount to the S&P. We believe the risk/reward is attractive at these levels and think there could be significant upside to shares if ZBH posts a couple of quarters of accelerating growth." (8/27/2018)
- 5. Canaccord Genuity analysts commented, "We are updating our model to reflect Zimmer’s adoption of several previously disclosed new accounting standards (revenue recognition for customer contracts, reporting of pension costs, and hedging activities). The company adopted the changes effective January 1, 2018, and recently provided updated historical financials (for 2016 and 2017) to reflect a retrospective adoption of the new standards. While the new accounting policies have not resulted in any material changes to 2016 and 2017 historical results, we have nonetheless updated our model to reflect how the company will report moving forward. Additionally, we have also tweaked our forward estimates to incorporate a slightly more conservative revenue ramp in 2018/2019 and higher COGS and operating spend related to the quality/manufacturing remediation and sales channel incentives/ investments. Thus we maintain our HOLD rating and lower our price target to $121." (4/12/2018)
Has Zimmer Biomet been receiving favorable news coverage?
Press coverage about ZBH stock has trended somewhat positive on Saturday, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zimmer Biomet earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Zimmer Biomet's key competitors?
Some companies that are related to Zimmer Biomet include Intuitive Surgical (ISRG), Edwards Lifesciences (EW), COLOPLAST A/S/ADR (CLPBY), Align Technology (ALGN), Smith & Nephew (SNN), Steris (STE), WILLIAM DEMANT/ADR (WILYY), MSA Safety (MSA), Wright Medical Group (WMGI), Inogen (INGN), Avanos Medical (AVNS), Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX) and Invacare (IVC).
Who are Zimmer Biomet's key executives?
Zimmer Biomet's management team includes the folowing people:
- Mr. Bryan C. Hanson, Pres, CEO & Director (Age 51)
- Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 54)
- Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 46)
- Mr. Sang Yi, Pres of Asia Pacific (Age 56)
- Mr. Kenneth R. Tripp, Sr. VP of Global Operations & Logistics
Who are Zimmer Biomet's major shareholders?
Zimmer Biomet's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.75%), Massachusetts Financial Services Co. MA (6.85%), JPMorgan Chase & Co. (5.68%), Longview Partners Guernsey LTD (3.23%), American Century Companies Inc. (2.17%) and Nordea Investment Management AB (2.02%). Company insiders that own Zimmer Biomet stock include Bryan C Hanson, Chad F Phipps, David A Jr Nolan, David C Dvorak, Katarzyna Mazur-Hofsaess, Sang Yi and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet.
Which major investors are selling Zimmer Biomet stock?
ZBH stock was sold by a variety of institutional investors in the last quarter, including Longview Partners Guernsey LTD, Massachusetts Financial Services Co. MA, Renaissance Technologies LLC, American Century Companies Inc., The Manufacturers Life Insurance Company , Deutsche Bank AG, Cannell Peter B & Co. Inc. and Mitsubishi UFJ Trust & Banking Corp. Company insiders that have sold Zimmer Biomet company stock in the last year include Chad F Phipps, Katarzyna Mazur-Hofsaess and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet.
Which major investors are buying Zimmer Biomet stock?
ZBH stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., OppenheimerFunds Inc., BlackRock Inc., Primecap Management Co. CA, Point72 Asset Management L.P., Tavio Capital LLC, TIAA CREF Investment Management LLC and Teachers Advisors LLC. View Insider Buying and Selling for Zimmer Biomet.
How do I buy shares of Zimmer Biomet?
Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zimmer Biomet's stock price today?
One share of ZBH stock can currently be purchased for approximately $117.05.
How big of a company is Zimmer Biomet?
Zimmer Biomet has a market capitalization of $23.03 billion and generates $7.82 billion in revenue each year. The medical equipment provider earns $1.81 billion in net income (profit) each year or $8.03 on an earnings per share basis. Zimmer Biomet employs 18,200 workers across the globe.
What is Zimmer Biomet's official website?
How can I contact Zimmer Biomet?
Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]
MarketBeat Community Rating for Zimmer Biomet (NYSE ZBH)
MarketBeat's community ratings are surveys of what our community members think about Zimmer Biomet and other stocks. Vote "Outperform" if you believe ZBH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZBH will underperform the S&P 500 over the long term. You may vote once every thirty days.
